Intended for healthcare professionals

Rapid response to:

Education And Debate

The marketing of a disease: female sexual dysfunction

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7484.192 (Published 20 January 2005) Cite this as: BMJ 2005;330:192

Rapid Response:

Re: Re: It is not only Big Pharma that says that female sexual dysfunction exists

I thank Petra Boynton for her comments. I agree that there are
difficulties in defining sexual dysfunction, and there is a great danger
in medicalising a condition for which many women seek no help, and which
they perceive as being 'normal for them'.

However, there is a cohort of individuals who do feel the need to
seek medical help, such as resulting from another medical problem that
leads to sexual difficulties. In this population, when testosterone levels
are found to be low, then a trial of testosterone may be warranted. It is
certainly not everyone who has a low testosterone, nor for everyone who
complains of sexual dysfunction. Thus, as with every drug prescribed, it
should be the discretion of the prescribing physician to decided if the
change in sexual function that the patient describes, along with the
condition that may have caused the change in androgen levels and thus the
change in sexual function.

Competing interests:
None declared

Competing interests: No competing interests

26 January 2005
Ketan K Dhatariya
Consultant Endocrinologist
Norfolk and Norwich University Hospital, Norwich, NR4 6PR